Henry Schein, Inc Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Queens NY United States (1932)
Status: Acquired by Watson Pharmaceuticals (2000) → now AbbVie (2019)

Organization Overview

First Clinical Trial
None
First Marketed Drug
1998
famotidine (pepcid)
First NDA Approval
None
Last Known Activity
2006

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

DIALYSIS SUPS

Active Ingredients

Marketed Drugs (4)

Key: Henry Schein, Inc (3) Acquired (1)

famotidine (pepcid) (1998)

magnesium (2006)

sodium bicarbonate (2006)

sodium chloride (2006)

Drugs in Phase 4 Trials (5)

Key: Henry Schein, Inc (0) Acquired (5)

interferon alpha-2b (Intron-A) (28 trials)

ivacaftor (Kalydeco) (98 trials)

lumacaftor (Orkambi) (24 trials)

ribavirin (virazole) (30 trials)

telaprevir (incivek) (38 trials)

Drugs in Phase 3 Trials (15)

Key: Henry Schein, Inc (0) Acquired (15)

acetaminophen (tylenol) (5 trials)

decernotinib (6 trials)

deutivacaftor (7 trials)

elexacaftor (Trifakta) (22 trials)

Exagamglogene autotemcel (Casgevy) (6 trials)

hydrocodone (hycodan) (5 trials)

Inaxaplin (4 trials)

tezacaftor (Trifakta) (50 trials)

tipiracil (lonsurf) (1 trial)

trifluridine (viroptic) (1 trial)

vanzacaftor (2 trials)

vitamin d3 (1 trial)

vx-210 (1 trial)

vx-548 (14 trials)

vx-659 (6 trials)

Drugs in Phase 2 Trials (35)

Key: Henry Schein, Inc (0) Acquired (35)

allogeneic pancreatic islet cells (1 trial)

avn-944 (3 trials)

BIRICODAR (1 trial)

bone autograft (1 trial)

calcium phosphate (1 trial)

cethrin (1 trial)

ctp-656 (4 trials)

cyclosporine (sandimmune) (2 trials)

daclatasvir (daklinza) (1 trial)

doxorubicin (Doxil) (2 trials)

lomibuvir (5 trials)

md05 (1 trial)

Merimepodib (1 trial)

p-1037 (1 trial)

pec-01 cells (3 trials)

pregabalin (lyrica) (1 trial)

recombinant human gdf-5 (1 trial)

sodium chloride (3 trials)

sofosbuvir (sovaldi) (1 trial)

tacrolimus (prograf) (2 trials)

vch-759 (1 trial)

vctx211 (1 trial)

vincristine (oncovin) (1 trial)

vx-135 (3 trials)

vx-150 (5 trials)

vx-152 (1 trial)

vx-371 (2 trials)

vx-440 (2 trials)

vx-670 (1 trial)

vx-702 (2 trials)

vx-765 (3 trials)

vx-787 (1 trial)

vx-814 (1 trial)

vx-864 (2 trials)

vx-880 (1 trial)

Drugs in Phase 1 Trials (33)

Key: Henry Schein, Inc (0) Acquired (33)

als-002158 (1 trial)

als-002200 (1 trial)

berzosertib (1 trial)

buprenorphine (1 trial)

carboplatin (paraplatin) (2 trials)

ciprofloxacin (cipro) (2 trials)

cisplatin (platinol) (2 trials)

digoxin (lanoxin) (1 trial)

etoposide (vepesid) (1 trial)

gemcitabine (gemzar) (2 trials)

itraconazole (sporanox) (3 trials)

methadone (methadose) (1 trial)

methylprednisolone (medrol) (1 trial)

midazolam (versed) (4 trials)

moxifloxacin (avelox) (4 trials)

naloxone (narcan) (1 trial)

omeprazole (prilosec) (1 trial)

prednisone (meticorten) (1 trial)

raltegravir (isentress) (1 trial)

rifampin (3 trials)

vch-916 (1 trial)

vctx210a (1 trial)

vx-522 (1 trial)

vx-634 (1 trial)

vx-668 (1 trial)

vx-708 (2 trials)

vx-803 (1 trial)

vx-828 (1 trial)

vx-840 (1 trial)

vx-973 (1 trial)

vx-984 (1 trial)

vx-985 (1 trial)

vx-993 (1 trial)

Drugs in Other Trials (1)

Key: Henry Schein, Inc (0) Acquired (1)

bosutinib (bosulif) (1 trial)

Indications

Overview

  • Highest Phase: None
  • # of Trials: 228
  • # of Trial APIs: 89